- Home
- ACIU vs TLS Comparison
ACIU vs TLS Comparison
Compare ACIU & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TLS
- Stock Information
- Founded
- ACIU 2003
- TLS 1969
- Country
- ACIU Switzerland
- TLS United States
- Employees
- ACIU N/A
- TLS N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TLS EDP Services
- Sector
- ACIU Health Care
- TLS Technology
- Exchange
- ACIU Nasdaq
- TLS Nasdaq
- Market Cap
- ACIU 332.4M
- TLS 238.1M
- IPO Year
- ACIU 2016
- TLS 2020
- Fundamental
- Price
- ACIU $3.12
- TLS $3.60
- Analyst Decision
- ACIU Strong Buy
- TLS Buy
- Analyst Count
- ACIU 2
- TLS 6
- Target Price
- ACIU $12.00
- TLS $4.80
- AVG Volume (30 Days)
- ACIU 146.5K
- TLS 573.5K
- Earning Date
- ACIU 11-05-2024
- TLS 11-12-2024
- Dividend Yield
- ACIU N/A
- TLS N/A
- EPS Growth
- ACIU N/A
- TLS N/A
- EPS
- ACIU N/A
- TLS N/A
- Revenue
- ACIU $48,505,404.00
- TLS $122,959,000.00
- Revenue This Year
- ACIU $85.33
- TLS N/A
- Revenue Next Year
- ACIU $80.69
- TLS $38.31
- P/E Ratio
- ACIU N/A
- TLS N/A
- Revenue Growth
- ACIU 4097200.00
- TLS N/A
- 52 Week Low
- ACIU $2.25
- TLS $1.89
- 52 Week High
- ACIU $5.14
- TLS $5.03
- Technical
- Relative Strength Index (RSI)
- ACIU 44.22
- TLS 53.22
- Support Level
- ACIU $3.10
- TLS $3.25
- Resistance Level
- ACIU $3.21
- TLS $3.70
- Average True Range (ATR)
- ACIU 0.12
- TLS 0.17
- MACD
- ACIU -0.02
- TLS 0.04
- Stochastic Oscillator
- ACIU 15.09
- TLS 83.33
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.